| Sex | Frequency | Percentage (%) | |||
| Male | 92 | 71.3 | |||
| Female | 37 | 28.7 | |||
| Age range (an) | Frequency | Percentage (%) | |||
| 19 - 24 | 4 | 3.1 | |||
| 25 - 30 | 23 | 17.8 | |||
| 31 - 36 | 25 | 19.4 | |||
| 37 - 42 | 28 | 21.7 | |||
| 43 - 48 | 20 | 15.5 | |||
| 49 - 54 | 17 | 13.2 | |||
| 55 - 60 | 8 | 6.2 | |||
| ≥61 - 66 | 4 | 3.2 | |||
| Average age: 40.05 ± 10.71 ans | |||||
| Therapeutic profiles | |||||
| Combinations (n, %) | Therapeutic treatment (n, %) | ||||
| 2INTI + 1INNTI | 2INTI + 1IP | 2INTI + 1INI | 2INTI + 1IP + 1INI | ||
| TDF + 3TC + EFV | 84 65.1 | 0 0 | 0 0 | 0 0 | |
| AZT + 3TC + ATV | 0 0 | 2 1.6 | 0 0 | 0 0 | |
| TDF + 3TC + DRV + RAL/r | 0 0 | 0 0 | 0 0 | 2 1.6 | |
| TDF + 3TC + DTG | 0 0 | 0 0 | 17 13.2 | 0 0 | |
| AZT + 3TC + LPV/r | 0 0 | 4 3.1 | 0 0 | 0 0 | |
| AZT + 3TC + NVP | 7 5.4 | 0 0 | 0 0 | 0 0 | |
| TDF + 3TC + ATV | 0 0 | 2 1.6 | 0 0 | 0 0 | |
| ABC + 3TC + LPV/r | 0 0 | 3 2.3 | 0 0 | 0 0 | |
| FTC + TDF + EFV | 1 0.8 | 0 0 | 0 0 | 0 0 | |
| D4T + 3TC + NVP | 1 0.8 | 0 0 | 0 0 | 0 0 | |
| TDF + 3TC + LPV/r | 0 0 | 5 3.9 | 0 0 | 0 0 | |
| AZT + 3TC + EFV | 1 0.8 | 0 0 | 0 0 | 0 0 | |
| Total | 94 72.9 | 16 12.4 | 17 13.2 | 2 1.6 | |
| Triple therapy = 127 (98.4%) | Quadrupletherapy 2 (1.6%) | ||||